|
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
RECRUITINGPhase 2Sponsored by Inova Health Care Services
Actively Recruiting
PhasePhase 2
SponsorInova Health Care Services
Started2026-09-04
Est. completion2027-09-30
Eligibility
Age18 Years – 98 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07831369
Summary
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Eligibility
Age: 18 Years – 98 YearsHealthy volunteers accepted
Inclusion Criteria: * Diagnosis of glioblastoma or IDH-mutated glioma by WHO 2021 classification * For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation * For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy * Evidence of progression by RANO 2.0 criteria on MRI within last four weeks * At least 1 enhancing measurable lesion Exclusion Criteria: * Use of an enzyme-inducing antiepileptic or other strong inducer of CYP3A4 * Prior treatment with irinotecan * Prior use of valproic acid within 2 months * Anticancer treatment within 4 weeks, 6 weeks if nitrosourea * Active bacterial or fungal infection requiring systemic treatment * Pregnancy * Known mitochondrial disease
Conditions3
Astrocytoma, IDH-Mutant, Grade 4CancerGlioblastoma
Interventions3
Locations1 site
Find trials near these locations
Related trials
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI — R-Pharm
- A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer — Multitude Therapeutics Inc.
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation — Genfleet Therapeutics (Shanghai) Inc.
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer — Beijing Konruns Pharmaceutical Co., Ltd.
- A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Qilu Pharmaceutical Co., Ltd.
- A Study of TXN10128 in Subjects With Solid Tumors — Txinno Bioscience Inc.
- AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer — Akeso
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorInova Health Care Services
Started2026-09-04
Est. completion2027-09-30
Eligibility
Age18 Years – 98 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07831369